Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06385769
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-26
First Post:
2024-04-22
Brief Title:
Transcutaneous Tibial Nerve Stimulation in Patients With Neurogenic Overactive Bladder After Stroke
Sponsor:
Pamukkale University
Organization:
Pamukkale University
Study Overview
Official Title:
Efficacy of Transcutaneous Tibial Nerve Stimulation in Patients With Neurogenic Overactive Bladder After Stroke A Randomized Placebo-controlled Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators conducted a prospective randomized double-blind placebo-controlled study based on the placebo technique to evaluate the efficacy of TTNS versus placebo in patients with OAB after stroke
The main questions aimed to be answered are
What are the effects of Trans Tibial Nerve Stimulation TTNS on incontinence-related clinical parameters and quality of life in patients with overactive bladder OAB after stroke compared to the placebo group Participants n22 with post-stroke AAM who meet the exclusion and inclusion criteria will be divided into 2 groups using a randomization table The first group will receive TTNS n11 and the second group will receive placebo TTNS n11 Measurements will be performed twice in total before treatment and at the end of treatment 4th week
The main questions aimed to be answered are
What are the effects of Trans Tibial Nerve Stimulation TTNS on incontinence-related clinical parameters and quality of life in patients with overactive bladder OAB after stroke compared to the placebo group Participants n22 with post-stroke AAM who meet the exclusion and inclusion criteria will be divided into 2 groups using a randomization table The first group will receive TTNS n11 and the second group will receive placebo TTNS n11 Measurements will be performed twice in total before treatment and at the end of treatment 4th week
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None